$67 M

BLPH Mkt cap, 20-Sep-2018
Bellerophon Therapeutics Net income (Q2, 2018)-7.4 M
Bellerophon Therapeutics EBIT (Q2, 2018)-16.4 M
Bellerophon Therapeutics Cash, 30-Jun-201823.4 M

Bellerophon Therapeutics Income Statement

Annual

USDFY, 2016

R&D expense

5.1 m

General and administrative expense

2.2 m

Operating expense total

7.3 m

EBIT

(7.3 m)

Income tax expense

(438 k)

Net Income

(7.4 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

R&D expense

9.5 m8.4 m7.1 m5.1 m4 m2.5 m3.3 m6.4 mwdxefcqufszuzezftuxetqsqxt12.2 m

General and administrative expense

4.6 m3.4 m4.3 m2 m1.2 m1.7 m1.4 m2.1 m4.2 m

Operating expense total

14.1 m11.9 m11.4 m7.1 m5.2 m4.2 m4.8 m8.5 m16.4 m

EBIT

(12.9 m)(11.6 m)(11.2 m)(7.1 m)(5.2 m)(4.2 m)(4.8 m)(8.5 m)(16.4 m)

Interest income

19 k27 k27 k30 k22 k22 k27 k99 k190 k

Income tax expense

5.4 m5.4 m

Net Income

(12.9 m)(11.6 m)(11.1 m)(7.1 m)(5.1 m)(4.2 m)(19.1 m)4.1 m(7.4 m)

Bellerophon Therapeutics Balance Sheet

Annual

USDFY, 2016

Cash

14.5 m

Current Assets

26.5 m

PP&E

1.4 m

Total Assets

29.7 m

Accounts Payable

2.8 m

Current Liabilities

6.5 m

Total Liabilities

11.7 m

Additional Paid-in Capital

142.2 m

Retained Earnings

(124.5 m)

Total Equity

18 m

Financial Leverage

1.7 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

62.9 m48.5 m23.9 m1.3 m1.3 m3.9 m13.5 m28.4 m23.4 m

Current Assets

73.6 m60.9 m46.9 m23.1 m18.6 m17.5 m23.2 m34.8 m28.8 m

PP&E

1.6 m1.5 m1.8 m1.7 m1.6 m1.5 m1.3 m935 k845 k

Total Assets

75.2 m62.4 m49.2 m31.2 m26.3 m22.8 m25.8 m35.9 m29.8 m

Accounts Payable

659 k966 k934 k641 k2 m2.2 m3.9 m4.6 m4.1 m

Current Liabilities

12.8 m11.2 m8.6 m7.3 m6.2 m4.8 m6.1 m8.4 m9 m

Total Liabilities

33.7 m37.6 m

Additional Paid-in Capital

131.5 m132.8 m134.9 m144.1 m176.9 m178.3 m

Retained Earnings

(67.1 m)(78.7 m)(89.9 m)(107.7 m)(112.9 m)(117.1 m)(143.6 m)(175.2 m)(186.7 m)

Total Equity

23.9 m20.1 m18 m800 k2.2 m(7.8 m)

Financial Leverage

1.3 x1.3 x1.3 x32.2 x16.2 x-3.8 x

Bellerophon Therapeutics Cash Flow

Annual

USDFY, 2016

Net Income

(23.8 m)

Depreciation and Amortization

(400 k)

Cash From Operating Activities

(17.2 m)

Cash From Investing Activities

12.2 m

Cash From Financing Activities

13.2 m

Free Cash Flow

(17.2 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(12.9 m)(11.6 m)(11.1 m)(7.1 m)(5.1 m)(4.2 m)(19.1 m)4.1 m(7.4 m)

Depreciation and Amortization

91 k181 k

Accounts Payable

659 k966 k934 k641 k2 m2.2 m3.9 m

Cash From Operating Activities

(444 k)(6.1 m)

Cash From Investing Activities

502 k

Cash From Financing Activities

(28 k)141 k

Bellerophon Therapeutics Ratios

USDY, 2018

Financial Leverage

-3.8 x
Report incorrect company information